Date:	Dec.5 <sup>th</sup> ,2022
Your Name:	_Wenjuan _Yang
Manuscript '	Title:_DANH7 mutations benefit colorectal cancer patients receiving immune checkpoint
inhibitors	
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	_ X	_None	
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_X_	_None	
	testimony			
-	Constant for attending	24		
7	Support for attending meetings and/or travel	_ x	_None	
8	Patents planned, issued or	_ X	_None	
	pending			
9	Participation on a Data	X_	_None	
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x_	_None	
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	Х	Nama	
11	Stock of Stock options	_^_	_None	
12	Receipt of equipment,	Х	None	
	materials, drugs, medical	-~-	_140110	
	writing, gifts or other			
	services			
13	Other financial or non-	_ X	_None	
	financial interests			
		<b></b>		
Ple	ease summarize the above co	onflict (	of interest in the fo	llowing box:
	None.			
Ple	ase place an "X" next to the	e tollow	ring statement to in	dicate your agreement:

Date:	Dec.5 <sup>th</sup> ,2022
Your Name:	_Zhengjie Shen
Manuscript <sup>3</sup>	Title:_DANH7 mutations benefit colorectal cancer patients receiving immune checkpoint
inhibitors	
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial XNone	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	_ X	_None		
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
_	educational events				
6	Payment for expert	_ X	_None		
	testimony				
_					
7	Support for attending	_ <b>X</b>	_None		
	meetings and/or travel				
8	Patents planned, issued or	_ X	_None		
	pending				
9	Participation on a Data	x_	_None		
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X_	_None		
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	Х	None		
11	Stock of Stock options	-^-	_None		
12	Receipt of equipment,	Х	None		
	materials, drugs, medical	-~-			
	writing, gifts or other				
	services				
13	Other financial or non-	_ X	_None		
	financial interests				
Ple	ease summarize the above co	onflict	of interest in the fo	llowing box:	
	None.				
Ple	Please place an "X" next to the following statement to indicate your agreement:				

Date:	Dec.5 <sup>th</sup> ,2022
Your Name:	:_ Ti Yang
Manuscript	Title:_DANH7 mutations benefit colorectal cancer patients receiving immune checkpoint
inhibitors_	
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	_ <b>X</b> None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
_	educational events	V 1			
6	Payment for expert testimony	<b>X</b> None			
	testimony				
7	Support for attending	V None			
,	meetings and/or travel	_ <b>X</b> None			
	meetings and, or traver				
8	Patents planned, issued or	<b>X</b> None			
0	pending	_ XNone			
	P				
9	Participation on a Data	<b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	_ <b>X</b> None			
12	Descint of annique out	V N			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	<b>X</b> None			
	services				
13	Other financial or non-	<b>X</b> None			
	financial interests				
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:		
	Name				
	None.				

Please place an "X" next to the following statement to indicate your agreement:

Date:	Dec.5 <sup>th</sup> ,2022
Your Name:	_ Mianhua Wu
Manuscript '	Title:_DANH7 mutations benefit colorectal cancer patients receiving immune checkpoint
inhibitors	
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	_ <b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	V N	
6	Payment for expert testimony	<b>X</b> None	
	testilliony		
7	Support for attending	V None	
,	meetings and/or travel	_ <b>X</b> None	
	meetings and of traver		
8	Patents planned, issued or	<b>X</b> None	
-	pending	_ ^NOTIC	
	. <b>.</b>		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V Nove	
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical writing, gifts or other	_ ANOTIC	
	services		
13	Other financial or non-	_ <b>X</b> None	
	financial interests		
DI-		auflick of iukouast in the fel	louing hou
PIE	ease summarize the above co	ominict of interest in the fol	ioming nox:
	None.		
Ple	ease place an "X" next to the	following statement to in	dicate your agreement: